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Neuronal microtubules support intracellular trans-
port, facilitate axon growth, and form a basis for
neuronal morphology. While microtubules in non-
neuronal cells are depolymerized by cold, Ca2+, or
antimitotic drugs, neuronal microtubules are unusu-
ally stable. Such stability is important for normal
axon growth and maintenance, while hyperstability
may compromise neuronal function in aging and
degeneration. Though mechanisms for stability are
unclear, studies suggest that stable microtubules
contain biochemically distinct tubulins that are
more basic than conventional tubulins. Transgluta-
minase-catalyzed posttranslational incorporation of
polyamines is one of the few modifications of intra-
cellular proteins that add positive charges. Here
we show that neuronal tubulin can be polyaminated
by transglutaminase. Endogenous brain transglu-
taminase-catalyzed polyaminated tubulins have
the biochemical characteristics of neuronal stable
microtubules. Inhibiting polyamine synthesis or
transglutaminase activity significantly decreases
microtubule stability in vitro and in vivo. Together,
these findings suggest that transglutaminase-cata-
lyzed polyamination of tubulins stabilizes microtu-
bules essential for unique neuronal structures and
functions.
INTRODUCTION
Neuronal microtubules (MTs) are biochemically and physio-
logically diverse. Multiple genes for a- and b-tubulins are ex-
pressed differentially during development and regeneration.
Tubulins are also subject to posttranslational modifications,
and contain a heterogeneous group of microtubule-associatedproteins (MAPs) (Luduen˜a, 1998). The functional consequences
of such diversity are thought to be generating MTs suited for
unique demands of cells. Neurons are unusually polarized, with
a single long axon and multiple branching dendrites. MTs in
axons may be very long (more than hundreds of microns in
axons), and axonal MTs are maintained for weeks or months at
considerable distances from sites of tubulin synthesis (>1 m in
some human nerves), imposing unusual constraints on neuronal
MTs. Unlike MTs in nonneuronal cells, which can be highly
dynamic (Desai and Mitchison, 1997), axonal MTs are more
stable, allowing them to act as a structural framework for the
neuron, serve as tracks for organelle transport, maintain cell
shape and connections, and define functional compartments
(Brady, 1993). Moreover, MTs in axons are not continuous with
a perikaryal microtubule organizing center or visible nucleating
structure (Yu and Baas, 1994). How can axonal MTs extend for
such distances and be stable for so long, yet retain the ability
to be modified in response to physiological stimuli? A simple
answer would be the presence of a significant fraction of stable
MTs. This stableMT fraction is important not only for cytoskeletal
organization in early neuronal development (Kirkpatrick and
Brady, 1994; Kirkpatrick et al., 2001) and axon maintenance
through adulthood, but also for structural rearrangement for
axon regrowth and targeting during regeneration (Brady, 1993).
More interestingly, the increases in MT stability correlate with
decreases in neuronal plasticity, and both occur during aging
and in some neurodegenerative diseases. Therefore, learning
about stable MT fragments, which are unique to neurons, is
crucial for understanding normal axonal development and
neuronal differentiation; this may also aid in identifying novel
therapeutic targets for neurodegeneration and regeneration.
The existence of a stable, biochemically distinct fraction of
axonal tubulin was demonstrated some years ago (Brady et al.,
1984; Sahenk and Brady, 1987). When preparing MTs from
brain extracts, a substantial amount of tubulin remains in the
pellet following low-temperature depolymerization. This fraction
is termed cold-insoluble, or cold-stable tubulin. A more exten-
sive differential extraction using cold and Ca2+ extractions to
produce labile, cold-stable, and cold/Ca2+-stable fractions wasNeuron 78, 109–123, April 10, 2013 ª2013 Elsevier Inc. 109
Figure 1. Effects of DFMO on Microtubule
Stability in 3-Month-Old Rat Optic Nerve
(A) Scheme for fractionation of axonal tubulin in
soluble (S1), cold-stable (S2), and cold/Ca2+-
stable (P2, CST) tubulin.
(B) Fluorographs of tubulin fractions from optic
nerve labeled by slow axonal transport (21 days
after injection of 35S-methionine in the eye of
control or DFMO-treated rats (7 days pretreat-
ment). Tubulin and neurofilament triplet proteins
are the major labeled protein species in the P2
fraction of control nerves. Tubulin consistently
shifted from P2 to S1 with DFMO treatment,
whereas neurofilaments remained in P2.
(C) Compared with control, DFMO treatments for
both 7 and 21 days significantly decreased stable
tubulin levels without affecting neurofilament
fractionation (see Table S1). Statistical analysis
was by Student’s t test. **p < 0.001. Error bars
indicate ±SEM.
See also Table S1 and Figure S1.
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axons. Using axonal transport to metabolically label MTs in rat
optic nerve, the cold/Ca2+-stable tubulin fraction (P2) was exam-
ined by 2D-PAGE. A striking difference was found between
tubulins in soluble and those in stable MTs: some tubulins in
P2 exhibited a significant basic shift during isoelectric focusing
(IEF) (Brady et al., 1984). This suggested that tubulins in stable
MTs were biochemically distinct from those in cold-labile MTs.
Specifically, cold-stable MTs contained tubulins significantly
more basic than predicted from sequence or observed in cold-
cycled MTs.
Stability of MTs has been related to differences in MAPs, spe-
cific tubulin isotypes, and posttranslational modifications, but no
factor has been identified that is sufficient to make MTs stable to
depolymerization by cold or elevated Ca2+. MAPs stabilize
cycled MTs in vitro (Chapin and Bulinski, 1992), but the increase
in stability is modest and MAPs partition with both stable and
labile MTs (Brady et al., 1984). Similarly, detyrosination and acet-
ylation of a-tubulin correlate with MT stability in many systems
(Bulinski et al., 1988), but in vitro these modifications confer no
measurable change in MT stability (Maruta et al., 1986; Webster
et al., 1990) and are found in all cell types. Specific tubulin iso-
types may contribute to MT stability (Falconer et al., 1994), but
none partitions specifically with stable MTs, and again, differ-
ences in stability are modest. The native pI values for highly
conserved tubulin isoforms all fall within a narrow range (pI =
5.5–5.6 for mouse a-tubulins, pI = 4.8–4.9 for mouse b2–6 tubu-
lins and pI = 5.6 for b1 tubulin). MAPs do not associate with
tubulin in IEF gels or change the charge on tubulins. Thus, no
known tubulin isotype or modification can account for both the
basic shift and exceptional stability of P2 tubulins, suggesting
a novel posttranslational modification.
The unusual IEF behavior of tubulin in cold-stable fractions
suggests the addition of a positive charge to affected subunits,
butmost familiarmodifications of cytoplasmic proteins are acidic
or neutral, including phosphorylation, acetylation, detyrosina-
tion, and glycosylation. One exception is covalent addition of a
polyamine, such as putrescine (PUT), spermidine (SPD), or sper-110 Neuron 78, 109–123, April 10, 2013 ª2013 Elsevier Inc.mine (SPM), to a protein-bound glutamine residue by a transglu-
taminase (Mehta et al., 2006). Polyamines are abundant multiva-
lent cations inmany tissues, present at high levels in brain (Slotkin
and Bartolome, 1986). Polyaminated proteins may exhibit un-
usual stability, increased insolubility, and resistance to proteoly-
sis (Esposito and Caputo, 2005). Ambron found that radioactive
polyamines were covalently linked to various neuronal proteins
in Aplysia, including a putative tubulin (Ambron and Kremzner,
1982). Polyamines and transglutaminase are abundant in brain,
but their physiological roles in neurons are notwell defined. How-
ever, increases in transglutaminase activity and polyamine levels
correlate with neuronal differentiation and neurite outgrowth
(Maccioni and Seeds, 1986; Slotkin and Bartolome, 1986).
The properties of polyamines and transglutaminase are con-
sistent with polyamination playing a role in stabilizing MTs.
We tested the hypothesis that polyamination of axonal tubulins
leads to generation of cold-stable MTs. When endogenous poly-
amine levels were lowered in rats using an irreversible inhibitor of
polyamine synthesis, cold-stable tubulin levels significantly
decreased. Both in vivo labeling of tubulin with radioactive
PUT and in vitro transamidation with monodansylcadaverine
(MDC, a fluorescent diamine) indicated that neuronal tubulin is
a substrate for polyamination by transglutaminase. Polyamine
modification sites were mapped by liquid chromatography-
tandem mass spectroscopy (LC-MS/MS) and were consistent
with sequence-specific incorporation of polyamines into neu-
ronal tubulins by transglutaminase. MTs containing transgluta-
minase-catalyzed polyaminated tubulins were resistant to
cold/Ca2+ depolymerization and had added positive charge,
mimicking neuronal stable MTs, which are largely restricted to
nervous tissues and highly enriched in axons in vivo. Further, a
mouse model in which the major brain transglutaminase isoform
2 (TG2) was knocked out had decreased neuronal MT stability.
Finally, TG2 was identified as playing a role in stabilizing MTs
in mouse brains at different postnatal times as neurons mature
and myelination of axons progresses. Transglutaminase-cata-
lyzed polyamination of tubulin was essential for neurite growth
and neuronal differentiation, as well as MT stability in culture.
Figure 2. Covalent Incorporation of Radiola-
beled PUT into Rat Optic Nerve with Tubulin
as a Putative Substrate
(A) A protein of tubulin size was labeled with 3H-PUT
(left) while the total protein fraction was labeled with
35S-methionine (right). 3H-PUT was incorporated
into axonal tubulin mainly in cold/Ca2+-stable tubulin
fractions (P2). 14C-PUT modified axonally trans-
ported P2 tubulin in a similar pattern (not shown).
(B) Upper: Gel filtration chromatography of 14C-
labeled P2 proteins in rat optic nerve at 21 day
ISI, indicating a single broad peak of radioactivity.
Lower: The peak of eluted radioactivity coincides
with tubulin immunoreactivity, consistent with co-
valent incorporation of polyamines into tubulin
in vivo.
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lyzed polyamination of neuronal tubulins contributes to MT
stability in axons and this posttranslational modification is impor-
tant for neuronal development and maturation.
RESULTS
Inhibition of Polyamine Synthesis Significantly
Decreases Axonal MT Stability
To determine whether polyamines are needed for cold/Ca2+-sta-
ble tubulin (CST), endogenouspolyamine levelswere loweredand
CSTevaluated in rat optic nerve. The rate-limiting enzyme in poly-
amine biosynthesis is ornithine decarboxylase (ODC) (Pegg and
McCann, 1988). Difluoromethylornithine (DFMO) is a suicide in-
hibitor of ODC. Administered to rats as a 2% solution in drinking
water, DFMO lowers total polyamine levels significantly in all tis-
sues examined (Danzin et al., 1979). Rats treated with DFMO for
2–21dayswereused todetermine theeffectsof reducedneuronal
polyamine on CST. After 18 hr, 7 days, and 21 days of treatment,
axonal MTs were labeled by injecting 35S-methionine into the
vitreous of the eye and waiting 21 days for axonal transport to
deliver labeled tubulin to the optic nerve. Cold/Ca2+ fractionation
of labeled optic nerve (Figure 1A) showed a significant decrease
in CST after DFMO treatment (Figures 1B and 1C). Fluorographs
of S1, S2, and P2 fractions from control and DFMO-treated rats
show a significant fraction of tubulin shifted from P2 to S1 frac-
tions with DFMO treatment (Figure 1B). In control optic nerves,
52% of the total radiolabeled axonal tubulin was cold-insoluble
tubulin, but in 7 day or 21 day DFMO-treated nerves, this fraction
was <40% (Figure 1C; see also Figure S1 available online; Table
S1) (p < 0.001), suggesting that polyamines are required for gen-
eration of cold-insoluble tubulin in axons. To determinewhether a
decrease in polyamines generally reduced cytoskeleton stability
in axons or was specific for MTs, neurofilament (NFM) fraction-
ation was analyzed in parallel. There was no change in NFM frac-
tionation after DFMO treatment (Table S1).
In Vivo Labeling of Tubulin with Radiolabeled
Polyamines
Next, we sought to determine whether polyamines were cova-
lently added to tubulin in vivo and whether modified tubulincofractionated with cold-insoluble tubulin. 14C-PUT axonal
transport labeling experiments were performed in rat optic
nerves. Due to high levels of endogenous polyamines and low
specific activity of 14C-PUT, endogenous polyamine levels
were lowered by 18 hr DFMO pretreatment. When axonal pro-
teins were fractionated 21 days after 14C-PUT labeling, 70%–
80%of the label was in P2 (not shown). Subsequent fractionation
studies with higher-specific-activity 3H-PUT confirmed these
results (Figure 2A). In optic nerves labeled by axonal transport
of 3H-PUT, the only proteins with significant incorporation of
labeled polyamines had the molecular weight (MW) of tubulin,
although 35S-methionine labeled neurofilaments at the same
time. Much lower levels of 3H-PUT were seen in S1, the cold-
labile MT fraction. This suggested that polyamination of tubulin
can occur before formation of stable MTs. Polyaminated tubulin
may help nucleate and stimulate polymerization of tubulins and
may also stabilize MTs after polymerization.
14C-PUT-labeled proteins in P2 were analyzed by gel fil-
tration chromatography on a Toyopearl HW-55F (Supelco)
column equilibrated in 6 M guanidine-HCl in MES to determine
if 14C-PUT coeluted with tubulin. A single broad peak of 14C
eluted 20–30 ml after the void volume coinciding with the peak
of tubulin immunoreactivity. There was no peak of 14C corre-
sponding to free polyamines (Figure 2B), suggesting that poly-
amines in CST fractions were covalently incorporated into
axonal tubulins.
Polyamination of Neuronal Tubulins and MTs In Vitro
In vivo stabilization of neuronal MTs by polyamines could occur
by covalent posttranslational modification of tubulins. To confirm
modification of tubulins with polyamines and evaluate a potential
role for transglutaminase, an enzyme known to catalyze polyami-
nation, purified mouse brain tubulin/MTs were incubated with
recombinant transglutaminase in vitro. In vitro transglutaminase
activity was controlled by addition of Ca2+. Transglutaminase
polyaminated both tubulin and polymerized MTs via a Ca2+-
dependent reaction. Modification was visualized in two ways:
First, MDC, a fluorescent diamine and transglutaminase sub-
strate (Lorand et al., 1971), was used as a polyamine analog,
giving a fluorescent band at the apparent MW of tubulin in
SDS-PAGE. This band was observed whether the substrateNeuron 78, 109–123, April 10, 2013 ª2013 Elsevier Inc. 111
Figure 3. In Vitro Polyamination of Neuronal Tubulin and MTs and Transglutaminase Activity
(A) SDS-PAGE showed a fluorescent band at tubulinMW, indicating covalent addition ofMDC to purifiedmouse tubulin andMTswith transglutaminase (gpTgase)
activity. This modification required Ca2+ to activate transglutaminase and was also seen with pig brain tubulin and MTs.
(B) SPM and SPD were also incorporated into neuronal tubulin. Immunoblotting for polyamine (red) and tubulin (green) showed polyaminated tubulins in yellow
(merge) (also see Figure S2). Neuronal MTs polymerized in vitro showed comparable tubulin modifications (not shown).
(C) gpTgase-catalyzed covalent addition of MDC was comparable for tubulin and taxol-stabilized MTs. Polyaminated proteins showed decreased solubility and
were enriched in pellets.
(D) Coomassie-blue-stained gel (left) showed similar amounts of tubulin and taxol-stabilized MTs as substrates for polyamination in (C). In the absence of
polyamines, transglutaminase catalyzed crosslinking of tubulins (right), but crosslinked tubulins were primarily in supernatants and could not enter the stacking
gel (not shown).
(E) Negative-stain electronmicroscopy (EM) showed polymerizedMTswith polyaminated tubulin. Several different magnification images show thatmanyMTs are
present in this fraction.
(F) Negative-stain EM showed crosslinked tubulin aggregates by transglutaminase in the absence of polyamines.
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Figure S2). Second, modified tubulins were visualized by immu-
noblot when physiological polyamines (SPM and SPD) were
used. Bands were identified as tubulin using the DM1A antibody
against a-tubulin, and polyamine modification was identified
with an anti-SPM/SPD antibody that recognizes both SPM and
SPD (Figure 3B). Both free tubulin and tubulin in MTs were modi-
fied by transglutaminase and SPM/SPD.
Polyaminated tubulins/MTs showed reduced solubility as the
bulk of modified tubulins were pelleted. When transglutaminase
was incubated with tubulin without polyamines, we observed
tubulin crosslinking, but crosslinked tubulin aggregates re-
mained in supernatants rather than pelleting, and much cross-
linked tubulin failed to enter the gel (Figures 3C and 3D). The
presence of polyamines in reactions largely eliminated crosslink-
ing. To determine whether modification of tubulin by transgluta-112 Neuron 78, 109–123, April 10, 2013 ª2013 Elsevier Inc.minase favors disassembled or polymerized tubulin, similar
amounts of free tubulins and taxol-stabilized MTs were incu-
bated in vitro with transglutaminase and polyamines. There
was no significant difference in incorporation of either MDC (Fig-
ures 3C and 3D) or SPM/SPD (data not shown). Patterns of poly-
amine modification on unassembled tubulins (Figures 3A–3D),
polymerized MTs (Figure 3A), and taxol-stabilized polymerized
MTs (Figures 3C and 3D) were similar. Electron microscopy
showed polyaminated tubulins polymerized in vitro at 37C (Fig-
ure 3E). In contrast, tubulin treated with transglutaminase
without polyamines formed large aggregates with no evidence
of MT formation (Figure 3F). Since intracellular polyamine levels
are high, crosslinking is unlikely to occur. These data suggest
that transglutaminase-catalyzed polyamination of tubulin occurs
on both tubulin and MTs, and that polyaminated tubulins poly-
merize normally.
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Tubulins
To verify covalent modification of tubulin and map modification
sites, purifiedmouse brain tubulin/MTsmodified in vitro by trans-
glutaminase were analyzed by LC-MS-MS. In independent ex-
periments, four different polyamines or analogs (PUT, SPD,
SPM, and DMC) all modified tubulin in vitro in a similar way, as
identified by LC-MS-MS (Figure 4). Similar results were observed
with tubulin from P2 cold/Ca2+-stable MTs in vivo (Figures S3A
and S3B). LC-MS-MS analysis of tubulin from S1 cold-labile
MTs failed to detect significant amounts of polyamine-modified
tubulins. Putative modification sites on both a- and b-tubulins
were mapped by MS1 spectra based on mass shift (Figures 4A
and 4B). Selective modification sites were not sensitive to spe-
cific polyamines used in vitro but did depend on the amino
acid sequence. Putative modification sites were confirmed by
MS/MS, based on specific ion shifts (Figures 4B–4E; see also
Figure S3C) and locations predicted relative to tubulin dimer
structure (Figures 4F and S3D). Conserved sites were identified
in multiple tubulin isoforms. Targeted MS/MS analysis verified
that the Q at position 13 of a conserved N terminus b-tubulin
tryptic peptide EIVHIQAGQCGNQIGAK (corresponding to the
highly conserved Q15 in the b-tubulin sequence) was a primary
modification site (Figure 4A). Q15 is present in all mouse and
human b-tubulin sequences (Figure S3C). Based on a predicted
tubulin dimer structure (Nogales et al., 1998), the Q15 residue is
adjacent to the hydrolyzable GTP in b-tubulin, allowing interac-
tion between polyamines and GTP, where it might affect GTP
binding and/or hydrolysis. Additional conserved sites were iden-
tified, including sites on both a- and b-tubulins (data not shown).
Modified residues on a-tubulins (Q31, Q128, Q133, Q256, and
Q285) were of particular interest, because they were on the sur-
face between a-tubulin and b-tubulin in adjacent dimers. Identi-
fication of modification sites in the interface between a- and
b-tubulin is consistent with the theory that polyamine modifica-
tion plays a role in MT stabilization.
Biochemical Characteristics of Polyaminated Brain
Tubulins Catalyzed by Endogenous Transglutaminase
To determine whether neuronal transglutaminase and endoge-
nous polyamines were sufficient to modify tubulins, we prepared
a crude extract of endogenous transglutaminase from fresh
1month mouse brains (Figure S4). The transglutaminase fraction
(S0) contains soluble brain tubulin and free polyamines. When
endogenous transglutaminase was activated by reaction buffer,
>70% soluble tubulin became cold/Ca2+ stable (Figure 5, aP2),
but <20% of initially soluble tubulins were converted to cold/
Ca2+-stable tubulin (Figure 5, ctrl) in buffer lacking added Ca2+.
Residual reactivity in control buffer may be due to endogenous
Ca2+ activation of transglutaminase, or to a higher sensitivity of
DM1A for unmodified tubulins. Finally, in a mix of unmodified
and polyaminated tubulins run on an IEF, modified tubulins had
more basic pIs than unmodified tubulins (Figures 5E and S4),
consistent with the presence of added positive charge. Although
the amount of modified tubulin was less than expected, it was
sufficient to stabilize MTs, favoring the hypothesis that polyami-
nated tubulins nucleate tubulin dimer assembly and may occur
as stable segments along MTs. Endogenous brain transglutami-nase-catalyzed polyaminated tubulins share similar biochemical
properties with CST in vivo, specifically, stability against cold/
Ca2+ and the presence of added positive charges. Thus, endog-
enous levels of polyamines and transglutaminase in brain are
sufficient to modify and stabilize brain tubulin.
Transglutaminase Activity and TG2 Protein Distribution
In Vivo
Cold/Ca2+-stableMTs are a characteristic of nervous tissue, with
little or none detectable in nonneuronal tissues, except in testes
(Figure 6A). Stable tubulin in testes may be associated with
flagellar MTs and the role of polyaminated tubulin there remains
to be determined.
Transglutaminase activity in brain results from multiple gene
products, including TG1, TG2, TG3 (Kim et al., 1999), and TG6
(Hadjivassiliou et al., 2008), but the primary cytoplasmic trans-
glutaminase in brain is thought to be TG2 (Bailey and Johnson,
2004). To understand the role of TG2 in producing CST, we
analyzed TG2 protein and enzymatic activity in brain gray matter
enriched in perikarya/dendrites (cerebral cortex, brain stem, and
spinal cord) and in white matter enriched in axons (optic and
sciatic nerves). CST levels were significantly higher (>50% of
total tubulin) in adult optic nerves than in cerebrum, which is
enriched in dendrites and perikarya. Axonal enrichment of CST
suggested a spatial correlation between transglutaminase activ-
ity and CST levels. Transglutaminase activity was elevated in
both optic and sciatic nerves (Figures 6B and 6C), consistent
with TG2 immunoreactivity (Figures 6D and 6E). Sciatic nerve
had less TG2 immunoreactivity than optic nerve (Figures 6D
and 6E), but sciatic nerve transglutaminase enzyme activity
was equivalent to that of the optic nerve (Figures 6B and 6C),
suggesting differential expression of transglutaminase isoforms
in CNS and PNS. Quantification of TG2 protein in axonal tracts
was normalized to actin, which is enriched in optic and sciatic
nerve relative to cerebral cortex, brain stem, and spinal cord,
so relative TG2 levels in optic/sciatic nerves (Figures 6D and
6E) are not directly comparable to other brain regions, but
good spatial correlation existed between transglutaminase
activity and CST distribution in nervous tissues.
Inhibition of Transglutaminase Activity Inhibited Neurite
Growth
Since MT stability is essential for neuronal structure and func-
tion, transglutaminase-catalyzed polyamination of tubulin may
affect neuronal morphology. To test this, SH-SY5Y neuroblas-
toma cells were differentiated by retinoic acid and BDNF in the
presence of 10 mM IR072 (Figure S5), an irreversible transgluta-
minase inhibitor. Both transglutaminase activity and TG2 protein
level were upregulated as cells differentiated and extended
neurites (data not shown), correlating with increased MT stability
(Figure 7). Inhibition of transglutaminase had a significant effect
on SH-SY5Y morphology (Figure 7B) compared with cells
treated with vehicle (Figure 7A). IR072-treated cells remained
viable but no longer proliferated, although they showed a pheno-
type more like that of undifferentiated SH-SY5Y cells. Average
neurite length was severely reduced from 76 mm in control
cells to 29 mm with IR072 (Figures 7C and 7D). Some control
SH-SY5Y cells put out extremely long neurites (>150 mm), butNeuron 78, 109–123, April 10, 2013 ª2013 Elsevier Inc. 113
Figure 4. Polyamination sites mapped on tubulins by Liquid Chromatography-Tandem Mass Spectrometry
Trypsin-digested peptides from in vitro modified mouse brain tubulin and in vivo stable and labile MT fractions were subjected to LC-MS. Several putative
modification sites from different tubulin isoforms were identified based on the mass shift. A representative modification site on a conserved glutamine residue (Q)
in N-terminal b-tubulins is illustrated.
(A) Diagram showing sequence ions for peptide EIVHIQAGQCGNQIGAK (PEIVH). Based on accurate mass for sequence ions (see below), the peptide contained
unmodified Q at positions 6 and 9, leaving only Q at position 13 (in red, Q15 in the b-tubulin sequence) as a modification site with PUT in vitro.
(B) Targeted tandemMS spectrum on ions derived from PUT-modified PEIVH (PUT-PEIVH) with m/z 632.004
3+ (peptide mass 1892.989, 1.06 ppm error) showed an
accurate mass shift of 199.1321 from y4 to y5, suggesting an additional shift of 71.07 as a result of one PUT (mass, 88.15148) added to Q15 with a loss of one NH3
(mass, 17.0306).
(legend continued on next page)
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Figure 5. Biochemical Similarities between
In Vitro Polyaminated Tubulins and In Vivo
Neuronal Cold-Stable Tubulins
Mouse brain soluble tubulins were polyaminated
in vitro by endogenous mouse brain trans-
glutaminase/polyamine and subjected to cold
Ca2+ fractionation (Figure S4).
(A–C) Coomassie-blue-stained gel (A), immuno-
blots with DM1A (a-tubulin) (B), and Tu27
(b-tubulin) (C). Compared to controls without
transglutaminase activation by addition of Ca2+,
modified tubulins showed a remarkable increase in
the cold/Ca2+-stable fraction (P2a).
(D) Quantitation of a-tubulin showed that >70%
soluble tubulins were converted to cold/Ca2+-
stable tubulins (P fraction in aP2 group) after
polyamination while most tubulin remained soluble
with cold (ctrl S1) or Ca2+ (ctrl S2) in the control
group. Statistical analysis was by Student’s t test.
**p < 0.001. Error bars indicate ±SEM.
(E) 2D PAGE showed a shift toward a basic pI
for polyaminated tubulins, consistent with added
positive charge on in vivo cold/Ca2+-stable tubulin
(see also Figure S2).
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long neurites. Cold/Ca2+ fractionations tested whether lack of
transglutaminase activity reduced MT stability as well as neurite
extension. IR072 decreased both cold-stable and cold/Ca2+-
stable tubulin levels, with more significant effects on cold/Ca2+
fractions (Figure 7E). These suggested that transglutaminase is
essential for early neurite development by generating stable
tubulin/MTs and possibly by enhancing MT polymerization.
Altered CST Formation in a TG2-KO Mouse
Our data suggested a direct role for TG2 in CST formation in the
CNS. To test this, we evaluated CST levels in brain and spinal(C and D) Chromatograms confirmed the presence of PUT-PEIVH in brain stable MT fraction (P8), suggesting th
modification is sequence specific. Detailed modification patterns on the precursor and its ion series were sh
peptide (SPM-PEIVH) were observed in the same fractions.
(E) A summary of peak areas for polyaminated PEIVH from mouse brain MT fractions showed significantly high
fractions (P) compared with labile MT fractions (S).
(F) Putative polyaminated sites on tubulins were shown in terms of the protein structure. Using coordinates fro
Protein Data Bank ID, 1TUB) for predicted structures for taxotere-bound tubulin dimer (Nogales et al., 1998
phosphates on the exchangeable GTP in b-tubulin. The structure was generated using Cn3D software (Natio
positively charged polyamines might stabilize GTP and affect hydrolysis, consistent with a role for polyamine
superimposed at Q15 to illustrate approximate dimensions of putrescine (red dashed circle) and spermine
b-tubulin GTP.
See also Figure S3 and Tables S2, S3, and S4.
Neuron 78, 109–cord of TG2-KO mice (Nanda et al.,
2001), where no TG2 immunoreactivity
was detectable (Figure 8A, upper band).
Total transglutaminase enzymatic activity
was reduced to <30% of wild-type (WT) in
both brain and spinal cord (Figure 8B and
8C). Although transglutaminase activity
and TG2 protein levels were comparable
in brains of 5 week and 5 month WT
mice, transglutaminase activity and TG2protein levels decreased significantly in 5 month WT spinal
cord relative to the corresponding levels in 5 week WT spinal
cord. CST levels (Figures 8D and 8E, black bars) and cold/
Ca2+-stable tubulin levels (Figures 8D and 8E, white bars) corre-
lated with transglutaminase activity/TG2 protein levels in brain.
CST levels were drastically reduced in 5 week TG2 KO mouse
brain and spinal cord relative to the levels in age-matched WT
mice. The drop remained in 5 month TG2 KO brain, but CST
and transglutaminase activity levels in 5 month TG2 KO spinal
cord were comparable to those seen in age-matched WTs,
where TG2 protein level is low. Compensation from other trans-
glutaminase isoforms (mainly TG1 and TG3) in brain maintainedat the samemodification occurs in vivo and that the
own in (D); peaks corresponding to SPM-modified
er levels of PUT-PEIVH and SPM-PEIVH in stable MT
m the Protein Structure database (MMDB ID, 8900;
), the conserved Q15 residue is located adjacent to
nal Library of Medicine). This location suggests that
s in modulating microtubule dynamics. Circles are
(gray circle). Note the potential for interacting with
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Figure 6. Characterization of Transglutami-
nase Activity and TG2 Protein Levels in the
Nervous System
(A) Cold/Ca2+-stable tubulin was enriched in brain
but was at or below levels of detection in non-
neuronal tissues other than testes. The stable
tubulin fraction in testes is presumably due to the
stable microtubules in sperm flagella and may not
be equivalent to the brain fraction. However, poly-
amines and TG2 are present in testes.
(B) Transglutaminase activity was present in various
neural tissues, including cerebral cortex (CC), brain
stem (BS), spinal cord (SC), optic nerve (ON), and
sciatic nerve (SN) from 5-week-old mice.
(C) Quantitative plots showed that trans-
glutaminase activity higher in axon-enriched com-
partments, like ON and SN, correlated with higher
MT stability in axons.
(D) TG2 protein was also expressed differentially in
various neural tissues. The same amount of total
protein was loaded in each lane. Actin and GAPDH
were loading controls. Actin was higher in axon-rich
domains (ON and SN), while GAPDH was lower in
axon-rich tissues as a fraction of total protein.
(E) Quantitative comparison shows that the TG2/
actin ratio was lower in SN than in ON, but SN ex-
hibited comparable levels of TG activity (C); thus,
other transglutaminase isoforms may contribute to
axonal transglutaminase activity, particularly in the
PNS. Statistical analysis was by Student’s t test.
**p < 0.001. Error bars indicate ±SEM.
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maintain the fundamental structure and function of the CNS in
this model. Future experiments knocking down other isoforms
to reduce further total transglutaminase activity will be needed
to see the phenotype due to complete elimination of transgluta-
minase and CST.
Upregulation of TG2 and CST during Brain Development
Increases in TG2 levels and activity between 5 weeks and
5 months of age (Figure 8) suggested that TG2 and stable
MTs play a role in neuronal maturation. Earlier studies indicated
that microtubule stability increased with axonal maturation and
myelination (Kirkpatrick and Brady, 1994), 2 weeks postnatal
in mouse. To test whether stabilization of axonal MTs during
this stage correlates with transglutaminase-catalyzed polyami-
nation of neuronal tubulin, we examined transglutaminase
activity and TG2 immunoreactivity in one hemisphere of mouse
brains at 10 days, 3 weeks, and 3 months (Figures 9A–9D).
Cold/Ca2+ fractionations were performed on the other hemi-
sphere (Figure 9E).
Both transglutaminase activity (Figures 9A and 9B) and TG2
immunoreactivity (Figures 9C and 9D) were low in 10 day brains,
increased to a similar extent in 3 week brains, and continued to
increase in 3 month brains. Correspondingly, cold-stable and
cold/Ca2+-stable tubulin levels rise concurrently (Figure 9E), indi-
cating a strong temporal and developmental correlation between
transglutaminase activity, TG2 expression, and MT stability in
postnatal development of mouse brain. The result may be to116 Neuron 78, 109–123, April 10, 2013 ª2013 Elsevier Inc.stabilize microtubules in vivo during axon maturation and later
stages of life, a process different from initiation and stabilization
of early neurite development.
DISCUSSION
Regulation of MT polymer dynamics remains an important topic
of study (Kueh and Mitchison, 2009). MTs are generally quite
dynamic in nonneuronal cells, consistent with their need to
rapidly reorganize during division or migration (Desai and Mitch-
ison, 1997). In contrast, neurons must balance two opposing
properties of MTs: stability and dynamics. Stability is needed
for axonal MTs to provide a structural framework and serve as
tracks for axonal transport, while dynamics are needed for
reorganization and repair during neurite growth and remodeling
of synaptic connections (Brady, 1993). Most MTs remain intact
for long periods of time in axons that may be >1 m long in
humans.
Consistent with the idea of increased stability of axonal MTs,
a large fraction of neuronal tubulin pellets after extraction with
cold, Ca2+, or antimitotic drugs: treatments that depolymerize
most nonneuronal MTs. Themorphological correlate of insoluble
tubulin is stable segments of MTs (Sahenk and Brady, 1987) that
are enriched in axons, continuous with labile MT polymer, and
may serve as nucleation sites for adding tubulin dimers to MTs
(Brady et al., 1984; Sahenk and Brady, 1987). Stable MTs pro-
vide a stable structural framework for neurons while acting as
axonal MT organizing centers to facilitate remodeling of MTs
Figure 7. Effects of Transglutaminase Inhi-
bition on Neurite Extension in SH-SY5Y
Cells
To determine functions of polyamination and MT
stability in neuronal development, we differenti-
ated SH-SY5Y neuroblastoma in the presence of
IR072 (Figure S5), an irreversible transglutaminase
inhibitor.
(A) Control SH-SY5Y cells were differentiated,
fixed, and stained with b III tubulin antibody.
Normal neurite extension and neuron-like pheno-
types were observed.
(B) SH-SY5Y cells differentiated in the presence of
the IR072 showed significant inhibition of neurite
outgrowth and a phenotype more like undifferen-
tiated SH-SY5Y cells.
(C) Length distribution of neurites for control SH-
SY5Y cells showed an average of 76 mmwith some
neurites >150 mm.
(D) Length distribution of neurites for differentiated
SH-SY5Y cells treated with IR072 showed a sig-
nificant shift toward shorter neurites, with an
average length of 29 mm and a few neurites
>90 mm. The difference in mean neurite length for
control and IR072-treated cells was statistically
significant (p < 0.00001). This suggests that
transglutaminase activity is required for efficient
elongation of neurites during differentiation of
SH-SY5Y cells.
(E) Cold/Ca2+ fractionations were done on SH-
SY5Y cells under three conditions (undifferenti-
ated, differentiated, and differentiated with IR072).
Statistical analysis was by Student’s t test. Error
bars indicate ±SEM. Western blots with DM1A
antibody (a-tubulin) showed that (1) in undifferen-
tiated cells with low transglutaminase activity and
TG2 protein levels, <10% of total tubulin was cold stable, with no cold/Ca2+-stable tubulin; (2) in fully differentiated cells where both transglutaminase activity and
TG2 proteins level peaked, the cold-stable tubulin level increased significantly to >40% of total tubulin and cold/Ca2+-stable tubulin was >20% of total tubulin);
(3) in differentiated cells treated with IR072 where transglutaminase activity was significantly reduced, cold/Ca2-stable tubulin was dramatically lowered, to
<10%. This suggests a strong correlation between transglutaminase activity and microtubule stability, both of which may contribute to neurite development.
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generation of this fraction was poorly understood and not ex-
plained by previously characterized tubulin modifications.
Stable axonal MTs have been isolated and characterized, as
reported in the literature (Brady et al., 1984). Tubulin in these
fractions is notable in two ways: (1) stable MTs are biochemically
distinct from cold-labile MTs; and (2) levels of axonally trans-
ported cold-insoluble tubulin correlate with axonal plasticity
and maturation. Stable MTs comprise a higher fraction of axonal
MTs than of nonaxonal MTs (dendrites and perikarya). Myelin-
deficient axons contain lower levels of CST (Kirkpatrick and
Brady, 1994; Kirkpatrick et al., 2001), and young neurons contain
lower levels of CST than do older neurons (Brady and Black,
1986; Kirkpatrick and Brady, 1994; Kirkpatrick et al., 2001).
These data suggest that cold-stable MTs play a role in neuronal
maturation, making the biochemical basis of MT cold stability a
subject of much interest.
Analysis of purified stableMTs by 2D-PAGE revealed a striking
difference between tubulins in labile and those in stable frac-
tions: a shift in pI suggested that some tubulins in the stable frac-
tion were more basic than predicted by primary sequence,
consistent with the addition of positive charge. Most familiarposttranslational modifications of tubulins in brain were acidic
(phosphorylation and glutamylation) or charge neutral (acetyla-
tion and detyrosination) (Janke andKneussel, 2010). The positive
charge implied a novel modification of tubulins.
A modification that adds positive charge to proteins is cova-
lent addition of polyamines by transglutaminase. Consistent
with this, a 56-kDa protein in Aplysia neurons was polyaminated
(Ambron and Kremzner, 1982). Given that polyaminated proteins
may be less soluble, polyamination of tubulinsmight explain cold
insolubility. The abundance of polyamines in postmitotic neu-
rons (Slotkin and Bartolome, 1986) and the presence of signifi-
cant transglutaminase activity in brain (De Vivo et al., 2009)
were consistent with this idea.
Polyamine levels are high in developing and adult nervous sys-
tems (Shaw and Pateman, 1973), and they affect neuron migra-
tion, axon outgrowth, and synapse formation (Slotkin and Barto-
lome, 1986). Polyamines are implicated in both normal brain
function and neuropathology, but their specific roles are poorly
defined. The major physiological polyamines are PUT, SPM,
and SPD, derived from L-ornithine, a product of arginine degra-
dation through activity of ODC, an enzyme expressed abun-
dantly in neuronal and nonneuronal cells (Pegg and McCann,Neuron 78, 109–123, April 10, 2013 ª2013 Elsevier Inc. 117
Figure 8. Neuronal MT Stability in 5 Week
and 5 Month TG2 KO Mouse Brains
(A) Immunoblots documented absence of TG2
immunoreactivity inTG2 KO mouse brain and
spinal cord. In WT controls, brain TG2 was ex-
pressed at similar levels in both age groups, but
spinal cord TG2 levels dropped at 5 months rela-
tive to those observed in 5 week mice.
(B) Transglutaminase activity was significantly
reduced in TG2 KO mouse brains compared with
age-matched WT mouse brains. Brain trans-
glutaminase activities were similar between the
two ages, paralleling TG2 protein levels.
(C) Spinal cord transglutaminase activity was
much lower in TG2 KO mice than in WT mice
at 5 weeks, but transglutaminase activity was
comparable in 5 month TG2 KO and WT mouse
spinal cord.
(D) Brain cold- and cold/Ca2+-stable tubulin levels
decreased drastically in TG2 KOmice for both age
groups, consistent with changes in TG2 protein
and transglutaminase activity. Residual trans-
glutaminase activity due to other transglutaminase
isoforms may contribute to cold/Ca2+-stable
tubulin formation.
(E) Spinal cord cold-stable tubulin and cold/Ca2+-
stable tubulin levels decreased in 5 week TG2
KO mice as compared to age-matched WT mice,
but levels of stable tubulins in 5 month TG2 KO
and WT groups were not significantly different,
consistent with TG2 protein expression and
transglutaminase activity. Other transglutaminase
isoforms may make a greater contribution to MT
stability in adult spinal cord. Statistical analysis
was by Student’s t test. **p < 0.001, *p < 0.005.
Error bars indicate ±SEM.
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propylamine from S-adenosylmethionine to PUT and SPD,
respectively. High levels of polyamine in brain and rapid changes
in ODC expression in response to various stimuli suggest that
polyamine levels are well regulated.
Transglutaminases are a family of enzymes activated by Ca2+
that can catalyze crosslinking of peptides and proteins by forma-
tion of g-glutamyl-ε-lysyl bonds (Griffin et al., 2002). However, in
the presence of poly/di/monoamines, transglutaminases cata-
lyze formation of g-glutamyl amine bonds (Folk et al., 1980).
There are eight transglutaminase genes in human and mouse
genomes, including secreted and intracellular forms (Esposito
and Caputo, 2005). TG4 and Factor XIII are typically secreted
and may contribute to extracellular functions, including having
a role in blood clotting. Modification of neuronal cytoskeletal
elements requires an intracellular tissue-type transglutaminase.
TG1, TG2, TG3, TG5, and possibly TG6 are likely to be intracel-
lular. Intracellular transglutaminase functions are not well under-
stood, but are assumed to modify or crosslink proteins.
TG2 is the primary intracellular tissue-type isoform in brain
(Cooper et al., 2002). TG2 activity is found in mammalian
CNS and PNS (Hand et al., 1993). Two features of brain trans-
glutaminase are noteworthy: (1) brain transglutaminase activity
increases during development and is linked to neuronal differen-118 Neuron 78, 109–123, April 10, 2013 ª2013 Elsevier Inc.tiation and neurite outgrowth; and (2) neuronal cytoskeletal ele-
ments are in vitro substrates of tissue-type transglutaminase
from guinea pig liver (Miller and Anderton, 1986; Selkoe et al.,
1982). The questions of whether these proteins, particularly
tubulin, are indeed physiological substrates of brain transgluta-
minase, and whether modified tubulin changes cytoskeletal
properties, remain to be addressed.
Eight independent lines of evidence support the idea that
polyamination of neuronal tubulin by transglutaminase contrib-
utes to MT stability (see model in Figure S6). First, lowering
endogenous polyamine levels by inhibiting polyamine synthesis
significantly decreases neuronal CST levels (Figure 1; Table
S1). The simplest interpretation is that decreasing polyamine
levels by DFMO reduces polyamination of tubulin and cold/
Ca2+-stable MT levels. Decreased polyamine levels may also
regulate cold-insoluble tubulin indirectly by decreasing transglu-
taminase activity, consistent with studies of transglutaminase
activity and polyamine levels in other systems (Melino et al.,
1988). Regardless, both mechanisms suggest that polyamina-
tion of tubulin plays a role in stabilizing axonal MTs.
Second, radioactive polyamines incorporated into protein are
delivered into axons with slow axonal transport of MTs (SCa).
Radiolabeled polyamines fractionate with stable MTs through
biochemical manipulations, migrate in SDS-PAGE with tubulin,
Figure 9. Characterization of Transglutaminase Activity, TG2 Protein, and Microtubule Stability in Postnatal Mouse Brain Development
To evaluate changes in transglutaminase activity and TG2 protein as neurons develop and mature, mouse brain was analyzed at 10 days (premyelination);
3 weeks (active myelination), and 3 months (mature adult neurons).
(A) Fluorescence intensity of MDC incorporated into casein shows significantly increased transglutaminase activity during postnatal brain development. During
this interval, neurite outgrowth plays a minimal role, but consolidation of synaptic connections and myelination progresses toward adult levels. Changes in
transglutaminase activity during this time may be related to axonal maturation, correlated with myelination.
(B) Quantitative analysis shows that transglutaminase activity increased 1.5- and 3-fold in 3 week and 3 month brains, respectively, as compared with 10 day
mouse brain.
(C) Consistent with changes in transglutaminase activity, TG2 protein levels in western blots increased. Kinesin (H2) immunoreactivity was a loading control.
(D) Similar changes in TG2 protein and activity levels occurred during postnatal mouse brain development.
(E) Alteration of MT stability during postnatal mouse brain development. Cold/Ca2+ fractionations were performed on mouse brain from the three age groups and
analyzed by immunoblot with DM1A antibody, which recognizes a-tubulin. Cold-stable and cold/Ca2+-stable tubulin levels are 45% and 25%, respectively, of
total tubulin at 10 days. At 3 weeks, cold-stable tubulin increased to 58% of total tubulin, of which cold/Ca2+-stable tubulin was 32%. At 3 months, cold-stable
tubulin increased to 64%, while cold/Ca2+-stable tubulin increased to 36%. Differences are statistically significant (**p < 0.001 between 10 day and 3 week
groups, *p < 0.05 between 3 week and 3 month groups, n = 6). Error bars indicate ±SEM.
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chromatography (Figure 2).
Third, transglutaminase modifies purified brain tubulin, poly-
merized MTs, and taxol-stabilized MTs in vitro by covalent
addition of polyamines (Figure 3). Both fluorescent analogs of
polyamines (MDC) and physiological polyamines (SPM and
SPD) can be linked to tubulin. MTs containing tubulins polyami-
nated by endogenous brain transglutaminase match endoge-
nous CST in two key respects: they are resistant to cold/Ca2+
treatments that normally depolymerize MTs, and they exhibit
increased positive charge (Figures 5 and S2). Although transglu-
taminase can stabilize substrates through inter- or intramolecu-
lar crosslinking (Esposito and Caputo, 2005), and intermolecular
crosslinks can be generated in vitro, crosslinked tubulin is almost
exclusively soluble (Figure 3D) and does not polymerize (Fig-
ure 3F), whereas polyaminated tubulin polymerizes into MTs
that are similar to stable MTs in vivo. Little tubulin crosslinking
is observed with physiological levels of polyamines. Polyamina-
tion of tubulin occurs on either free tubulins or preassembled
MTs. Modification of soluble tubulin dimers may enhance poly-
merization by generating nucleating seeds, and modification of
assembled MTs may increase stability.
Fourth, both a- and b-tubulins have conserved polyamination
sites. A prominent modification is the conserved Q15 of
b-tubulin, positioned where it may affect GTP hydrolysis by
tubulin. Mass spectrometry identified additional modificationsites largely on interfaces where a/b-tubulin dimers interact
during polymerization. All identified locations are consistent
with a role in facilitating and/or stabilizing MT formation.
Fifth, cold stable tubulin is a hallmark of nervous tissue; with
little or none detectable in nonneuronal tissues (Figure 6). In vivo
transglutaminase activity and TG2 protein levels correlate with
stable MT levels in nervous tissues. Axonal MTs (e.g., optic
and sciatic nerve) are enriched in cold/Ca2+-insoluble tubulins,
and axon tracts exhibit a higher transglutaminase activity. Frac-
tionation of different neuronal tissues reveals elevated transglu-
taminase activity in both optic and sciatic nerve (Figure 6). The
spatial correlation between neuronal tubulin stability and trans-
glutaminase activity is consistent with a functional role for poly-
aminated tubulins in axons. Curiously, transglutaminase activity
was comparable in both CNS and PNS axon-rich regions, but
TG2 protein level was much higher in optic than in sciatic nerve.
Although TG2 is the major tissue-type transglutaminase isoform
in brain (Ruan and Johnson, 2007), other tissue-type transgluta-
minases may contribute to transglutaminase activity in the PNS.
Sixth, inhibiting transglutaminase activity reduces MT stability
significantly in culture and inhibits neurite outgrowth in differen-
tiating neuroblastoma cells (Figure 7). Although transglutami-
nase activity and stable MT levels are relatively low in immature
cells, they increase concurrently with differentiation, facilitating
extension and stabilization of neurites. This suggests that polya-
mination of tubulins by transglutaminase is involved in neuronalNeuron 78, 109–123, April 10, 2013 ª2013 Elsevier Inc. 119
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cytoskeletal structures during this process may be modulated
by tubulin polyamination, which may nucleate new microtubules
and stabilize polymerized MTs.
Seventh, brain and spinal cord from TG2 KO mice have
reduced MT stability, consistent with lower transglutaminase
activity and absence of TG2 (Figure 8). MT stability was signifi-
cantly reduced where there was a drop in transglutaminase
activity, e.g., in 5 week and 5 month TG2 KO brains and in
5 week TG2 KO spinal cords. However, MT stability remains
high in regions where transglutaminase activity is not signifi-
cantly reduced. Thus, MT stability and transglutaminase activity
were comparable in 5 month spinal cord for both TG2 KO and
WT mice, although TG2 immunoreactivity was eliminated in
TG2 KO. Maintenance of transglutaminase activity without
detectable TG2 in TG2 KO mice suggests involvement of other
transglutaminases in stabilizing MTs in spinal cord and, to a
lesser extent, in brain. Thus, cold/Ca2+-insoluble tubulin levels
were reduced but not eliminated in TG2 KO mice. Identifying
transglutaminase isoforms responsible for transglutaminase
activity in TG2 KO brain and WT spinal cord requires further
study. Regardless, correlations between transglutaminase
activity and MT stability in WT and TG2 KO mouse models are
consistent with our hypothesis that transglutaminase activity is
a major contributor to stable MT formation in vivo.
Eighth, transglutaminase activity and TG2 protein levels corre-
late with MT stability during development and maturation in vivo.
As axons mature and neuronal connections stabilize in response
to various postnatal modifiers, such as myelination, cold/Ca2+-
insoluble tubulin levels increase (Kirkpatrick and Brady, 1994;
Kirkpatrick et al., 2001). Correspondingly, transglutaminase pro-
tein levels and enzymatic activity are elevated (Figure 9). This
suggests that developmental regulation of transglutaminase
contributes to MT stabilization as the brain matures.
The role for transglutaminase activity and polyamines in stabi-
lization of axonal MTs does not preclude their playing other roles
in the nervous system. Transglutaminases are proposed to be
involved in neuronal development (Bailey and Johnson, 2004;
Maccioni and Seeds, 1986; Mahoney et al., 2000; Tucholski
et al., 2001) and signaling (Basso et al., 2012; Dai et al., 2008;
Facchiano et al., 2010), as well as in neurodegenerative diseases
(Bailey et al., 2005; Basso et al., 2012; De Vivo et al., 2009; Ruan
and Johnson, 2007).
Transglutaminase activity and polyamine levels correlate with
brain maturation, neuronal differentiation, and formation of neu-
rites (Bailey and Johnson, 2004), but the underlying mechanisms
are unclear. Here we propose that a key pathway for regulating
neuronal development is modulation of MT stability by TG2-
catalyzed polyamination of tubulins. Increases in both TG2
protein and transglutaminase activity increased stable MTs in
postnatal brains (Figure 9), concurrent with myelination and sta-
bilization of neuronal circuitry. Molecular pathways responsible
for effects of myelination on TG2 protein level and transglutami-
nase activity are under investigation. Transglutaminase activity
may also contribute to changes in cellular morphology (Gentile
et al., 1992). Depletion of polyamines results in the disappear-
ance of actin and MT bundles (Pohjanpelto et al., 1981). Inhibi-
tion of polyamine biosynthesis results in defects of neuronal120 Neuron 78, 109–123, April 10, 2013 ª2013 Elsevier Inc.morphogenesis, whereas exogenous polyamines stimulate adult
neurogenesis (Malaterre et al., 2004). All these are consistent
with our findings and suggest a common pathway based in
part on alteration of MT dynamics and stability through polyami-
nation of tubulin by TG2.
Stabilizing MTs by transglutaminase and polyamines has
many positive aspects for normal cytoskeletal structure and
function in developing brain, but may be a double-edged sword
in the aging nervous system. Transglutaminase activity and
polyamine levels increase in the aging brain (Lesort et al.,
2000; Slotkin and Bartolome, 1986) and are associated with
neurodegenerative diseases including Huntington’s (HD), Alz-
heimer’s, and Parkinson’s diseases (Jeitner et al., 2009; Lesort
et al., 2000). Functional consequences of these increases may
be complex. For example, exogenous polyamines and transglu-
taminase can be either neuroprotective or neurotoxic depending
on dose and context. Similarly, changes in MT stability may be
beneficial or detrimental depending on level and circumstance.
Stable MTs correlate positively with neuronal stability but
negatively with neuronal plasticity. The stable-MT fraction is
modest but crucial in early development, facilitating axon growth
and plasticity. As neurons mature, MT stability increases and
neuronal plasticity decreases. As a consequence, neuronal con-
nectivity may be stabilized, maintaining neuronal architecture,
but continued declines in plasticity in aging may limit axonal re-
covery following injury or in neurodegenerative diseases by
limiting MT dynamics. For example, inhibiting transglutaminase
in models of HD resulted in a modest improvement of lifespan
and behavior in HD mouse models. Although transglutaminase
may not be a direct component of molecular pathogenesis in
HD, it may compromise the ability of neurons to respond to
pathological changes by limiting sprouting and formation
of new connections. Understanding changes in cytoskeletal
dynamics and stability in development and neurodegeneration,
including but not limited to regulation of MT stability, will greatly
expand our knowledge of the MT cytoskeleton in health and
disease.
EXPERIMENTAL PROCEDURES
All chemicals used were American Chemical Society quality or better, from
Sigma, Invitrogen, CalBiochem, or Polysciences. Animals used include
Sprague/Dawley rats (200–225 g, Harlan), male C57BL/6 (Jackson Labora-
tories) and TG2 KO mice (Nanda et al., 2001). Axonal transport in rat optic
nerve was labeled by intravitreal injection of 35S-methionine or polyamines
(3H or 14C-PUT), as described previously (Brady and Lasek, 1982). An injec-
tion-sacrifice interval (ISI) of 21 days positioned the SCa wave containing
stable and labile MTs in the optic nerve. Radioactive proteins were analyzed
by SDS-PAGE and fluorography (Kirkpatrick et al., 2001). Our standard proto-
col for cold/Ca2+ fractionation of neuronal tubulins was used (Brady et al.,
1984) (Figure 1; Supplemental Information).
Following cold/Ca2+ fractionation, samples were separated on gradient gels
as described and transferred to Immobilon-P membrane (Millipore). Primary
antibodies include DM1A (1:20,000, Sigma) for a-tubulin, TGMO1 (1:4000)
for TG2, H2 (1:50,000) (Pfister et al., 1989) for kinesin heavy chain, Tu27
(1:10,000, provided by Dr. A. Frankfurter [Caceres et al., 1984]) for b-tubulin,
A2066 (1:5000, Sigma) for b-actin, and pab0022 and pab0023 (1:1200,
Covalab) for SPM/SPD.
For quantitative immunoblots, the secondary antibody was rat anti-mouse
IgG (1:1000, Jackson) detected with 125I-Protein A and measured by Phos-
phorImager (Molecular Dynamics) for quantitation with ImageQuant. For
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Stable Axonal Microtubules and Transglutaminasefluorescent quantitative immunoblots imaged by Typhoon 9410 (GE Health-
care), secondary antibodies were Cy5-anti-rat (1:400, Jackson) for TG MO1,
Cy5-anti-rabbit (1:400, Invitrogen) for pab022 and pab023, and Cy3-anti-
mouse (1:400, Jackson) for the rest.
All studies involving rats or mice were conducted under protocols approved
by the appropriate institutional animal care and use committees. All protocols
follow established institutional and NIH guidelines for the care and use of
vertebrate animals. Difluoromethylornithine (Merrell Dow) was administered
as a 2% solution in drinking water. DFMO was given to rats 16–18 hr prior
to labeling of axonal transport with 35S-methionine, and continued for 48 hr,
7 days, or all 21 days of a 21-day ISI. Control rats did not receive DFMO.
To lower endogenous polyamine levels and facilitate protein labeling with
labeled PUT (14C or 3H), DFMO was given 16–18 hr prior to labeling. Following
a 21- to 60-day ISI, rats were sacrificed and the optic nerve-optic tract
removed for cold/Ca2+ fractionation. P2 fractions were resuspended in 8 M
urea and run on a 60 ml Toyopearl HW-55F (Supelco) column equilibrated
in 6 M guanidine-HCL in 100 mM MES (pH 6.8). Total a-tubulin was detected
with DM1A.
Tubulin was purified from mouse brains through two cycles of polymeriza-
tion, as described (Castoldi and Popov, 2003). For polymerized MTs, tubulin
(50 mM) was incubated in BR buffer 1980 (BRB80) supplemented with 2 mM
GTP at 37C for 30min. For Taxol stabilization, taxol was added stepwise equi-
molar to tubulin in warm BRB80 buffer supplemented with 1 mM dithiothreitol
(DTT) and 1mMGTP and incubated at 37C for 30min. PolymerizedMTs were
pelleted over a glycerol/BRB80 cushion (http://mitchison.med.harvard.edu/
protocols.html).
In vitro polyamination assays used N,N0-dimethylcasein or tubulin/MTs as
a transglutaminase substrate; with MDC or a polyamine mix (SPM/SPD);
and guinea pig transglutaminase (similar to TG2 in brain) in reaction buffer
(pH 7.5) ± 10 mM Ca2+ at 37C for 60 min. Reactions were stopped by
20 mM cystamine and analyzed by SDS-PAGE. Fluorescence due to MDC
incorporation into tubulin was detected by Gel Doc 2000 (Bio-Rad).
For endogenous transglutaminase activity assays, transglutaminase
extract (150 mg) was incubated with 0.2 mg/ml N,N-dimethylcasein, 4 mM
MDC, 5 mM DTT in Tris-HCl-based reaction buffer (pH 7.5) with 10 mM
Ca2+ at 37C for 60 min. Transglutaminase extracts were prepared from
mouse brain by homogenization in 50 mM cold Tris-HCl, 1 mM EDTA,
0.25 M sucrose, 0.4 mM DTT, and protease inhibitor cocktail (Sigma).
Homogenates were centrifuged at 16,000 g at 4C for 20 min. Pellets were
discarded and the supernatant centrifuged at 100,000 g at 4C for 1 hr to
produce the endogenous transglutaminase extract containing transglutami-
nase, soluble tubulins, and polyamines. A tubulin pellet obtained by centrifu-
gation after stopping polyamination by cystamine was subjected to cold/Ca2+
fractionation.
Polyaminated and native tubulins were analyzed in 2D PAGE after solu-
bilization in 8 M urea, 4% CHAPS, 65 mM DTE, 0.5% ampholytes, and
bromophenol blue. Protein solution was cleared and absorbed onto a 7 cm
immobilized pH gradient pH 3–10 IPG strip (GE Bioscience) and run for
60 kVhr at room temperature. Before SDS-PAGE, IPG strips were equilibrated
and transferred to the top of 4%–12% Nu-Page gels held in position with
0.5% agarose.
In vitro polyaminated tubulins were prepared fresh with MDC, PUT, SPM, or
SPD and digested overnight with trypsin; unmodified tubulin was used as a
control. Samples were analyzed by LC-MS-MS (Thermo LTQ-FT Ultra) using
Agilent Zorbax SB300-C18 0.075 mm ID3 150 mm capillary analytical column
with 0.3 mm ID3 5mm Zorbax SB300 C18 trapping 250 nL/min gradient, 5%–
65% acetonitrile. Nano ESI Positive Ion mode (resolution 50,000 @m/z 400,
Scan 400–1800 m/z) was performed. The top three +2 and greater charged
ions for MS/MS from eachMS scan were selected. Putative modified peptides
were picked based on mass shift in MS1, and specific modification sites were
evaluated in MS2 spectra and confirmed through target runs. Searches using
MASCOT (version 2.2.04, Matrix Sciences) and MassMatrix search engines
against the SwissProtKB using mouse, carbamidomethylation, and methio-
nine oxidation as variable modifications in addition to PUT, SPM, and SPD
as variable modifications of Q. Searches were performed using 10 ppm pep-
tide tolerance and 0.6 Da fragment tolerance with decoy database searches
to keep false discovery rates below 5%.Synthesis and purification of TG2 selective irreversible inhibitor, IR072
(Figure S5), was as described previously (Chabot et al., 2010) using Fmoc
chemistry for solid-phase peptide synthesis. Details of synthesis and charac-
terization of IR072 are given in the Supplemental Experimental Procedures.
For cell culture, SH-SY5Y cells (from ATCC) were grown in DMEM F12
medium (GIBCO) supplemented with 10% FBS, PenStrep, and 2 mM gluta-
max. To produce a neuronal phenotype, cells were plated on polylysine-
coated wells or coverslips to 60% confluency. Differentiation was induced
by (1) 10 mM retinoic acid in 2% FBS for 2 days followed by 10 mM retinoic
acid in serum-free medium for 3 days; (2) 50 ng/ml BDNF in serum-free
medium for 5 days (Szebenyi et al., 2003). To test the role of transglutaminase
in differentiation and neurite outgrowth, cells were treated with the TG2 inhib-
itor IR072 at 10 mM in media during differentiation. Neurite outgrowth assays
were a modification of previously described methods (Szebenyi et al., 2003;
see Supplemental Experimental Procedures). Statistical significance was
determined by a paired sample t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four tables, six figures, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.neuron.2013.01.036.
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